Sugi Predict

Sugi Predict / Compounds / SCHEMBL16248678

SCHEMBL16248678

SCHEMBL16248678

CC(=O)OCC1O[C@@H](OCCCCCCOCc2ccccc2)C(C)[C@@H](C)[C@H]1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ SSTR1 P30872 1/20 0.41
▸ SSTR2 P30874 1/20 0.41
▸ SSTR4 P31391 1/20 0.41
▸ SSTR3 P32745 1/20 0.41
▸ SSTR5 P35346 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ NAAA Q02083 1/20 0.41
▸ KMT2A Q03164 1/20 0.40
▸ TACR1 P25103 3/20 0.40
▸ CYP2D6 P10635 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ TSHR P16473 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ CYP2C9 P11712 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ NT5E P21589 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27098290 0.90 LMNA (0.49) LMNASSTR1SSTR2SSTR4SSTR3
SCHEMBL27098269 0.89 LMNA (0.50) LMNASSTR1SSTR2SSTR4SSTR3
SCHEMBL17589419 0.89 ALDH1A1 (0.41) LMNASSTR1SSTR2SSTR4SSTR3
SCHEMBL16248647 0.88 ALDH1A1 (0.42) LMNAALDH1A1KMT2ACYP2D6MAPK1
SCHEMBL9604424 0.88 ALDH1A1 (0.42) LMNAALDH1A1KMT2ACYP2D6MAPK1
SCHEMBL16248744 0.86 TGM2 (0.46) LMNAALDH1A1TACR1L3MBTL1MAPT
SCHEMBL18875810 0.86 LMNA (0.38) LMNASSTR1SSTR2SSTR4SSTR3
SCHEMBL12252788 0.84 LMNA (0.41) LMNASSTR1SSTR2SSTR4SSTR3
SCHEMBL16248755 0.84 ALDH1A1 (0.45) LMNAALDH1A1KMT2ACYP2D6MAPK1
SCHEMBL17446637 0.84 HTT (0.46) LMNAALDH1A1KMT2AL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357776-A1 COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2023-11-09 — — US disclosed
US-11732265-B2 Compositions and methods for modulating complement factor B expression IONIS PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-20230151365-A1 COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2023-05-18 — — US disclosed
US-9714421-B2 Compositions and methods IONIS PHARMACEUTICALS, INC. (US) 2017-07-25 — — US disclosed
US-20170183661-A1 COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2017-06-29 — — US disclosed
US-20170166899-A1 COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2017-06-15 — — US disclosed
US-20170159055-A1 COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2017-06-08 — — US disclosed
US-20160354476-A1 TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE IONIS PHARMACEUTICALS, INC. (US) 2016-12-08 — — US disclosed
US-20160194349-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2016-07-07 — — US disclosed
US-9382540-B2 Compositions and methods for modulating angiopoietin-like 3 expression ISIS PHARMACEUTICALS, INC (US) 2016-07-05 — — US disclosed
US-20160017323-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE ISIS PHARMACEUTICALS, INC. (US) 2016-01-21 — — US disclosed
US-9181549-B2 Conjugated antisense compounds and their use ISIS PHARMACEUTICALS, INC. (US) 2015-11-10 — — US disclosed
US-20150315594-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-11-05 — — US disclosed
US-9163239-B2 Compositions and methods for modulating apolipoprotein C-III expression ISIS PHARMACEUTICALS, INC. (US) 2015-10-20 — — US disclosed
US-9145558-B2 Compositions and methods for modulating HBV expression ISIS PHARMACEUTICALS, INC. (US) 2015-09-29 — — US disclosed
US-9127276-B2 Conjugated antisense compounds and their use ISIS PHARMACEUTICALS, INC. (US) 2015-09-08 — — US disclosed
US-20150176007-A1 COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-06-25 — — US disclosed
US-20150126719-A1 COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-05-07 — — US disclosed
US-20150126718-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE ISIS PHARMACEUTICALS, INC. (US) 2015-05-07 — — US disclosed
US-20140343123-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE ISIS PHARMACEUTICALS, INC. (US) 2014-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354476-A1 TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE FUT6, GALNT6, FUT5 LMNA 993/4885SSTR1 3032/4885SSTR2 2643/4885
US-20230151365-A1 COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION TTR, GALNT1, GALNT3 LMNA 885/4885SSTR1 3672/4885SSTR2 3848/4885
US-20160194349-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION TEK, PLIN3, FABP3 LMNA 930/4885SSTR1 3930/4885SSTR2 3531/4885
US-20150176007-A1 COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION HAVCR2, HCCS, HDGF LMNA 823/4885SSTR1 4858/4885SSTR2 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.